Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TriSalus Life Sciences, Inc. - Common Stock (NQ: TLSI )

5.550 -0.140 (-2.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,555
Open 5.850
Bid (Size) 5.550 (4)
Ask (Size) 5.710 (2)
Prev. Close 5.690
Today's Range 5.550 - 5.850
52wk Range 3.320 - 16.24
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
From TriSalus Life Sciences
Via Business Wire

Performance

YTD
-32.73%
-32.73%
1 Month
-6.25%
-6.25%
3 Month
-42.90%
-42.90%
6 Month
-36.21%
-36.21%
1 Year
-53.75%
-53.75%

More News

Read More
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
From TriSalus Life Sciences
Via Business Wire
Crude Oil Rises 1%; Verastem Shares Slide
Via Benzinga
Exposures Fossil Fuels
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Nasdaq Gains 1%; Intuit Shares Plunge
Via Benzinga
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
From TriSalus Life Sciences
Via Business Wire
TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
TriSalus Reports Q1 2024 Financial Results and Business Update
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
From TriSalus Life Sciences
Via Business Wire
TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
From TriSalus Life Sciences
Via Business Wire
Earnings Scheduled For April 1, 2024
Via Benzinga
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors
From TriSalus Life Sciences
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update
From TriSalus Life Sciences Inc.
Via Business Wire
TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call
From TriSalus Life Sciences Inc.
Via Business Wire
Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications
From TriSalus Life Sciences Inc.
Via Business Wire
TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
From TriSalus Life Sciences Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.